- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01738607
Dietary Fiber for Fecal Incontinence
The Impact of Fiber Fermentation on Fecal Incontinence
Study Overview
Status
Conditions
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55455
- University of Minnesota
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- age ≥18 years
- living in the community (not a nursing home or assisted living facility)
- self-report of usually having FI of loose or liquid consistency at least twice in a 2-wk period
- toilets independently
- ability to read and write in English.
- Persons that regularly performed pelvic floor muscle exercises and/or biofeedback on a maintenance regimen for at least 20 wks or who took a steady dose of anti-motility medications on a regular schedule that still met the FI criteria were also eligible.
Exclusion Criteria:
- difficulty swallowing,
- a gastrointestinal (GI) tract altered by surgery,
- a malabsorption disorder,
- inflammatory bowel disease,
- gastrointestinal cancer or active cancer treatment,
- allergy to the fibers,
- regularly used a laxative or enema, were tube-fed, or unwilling to discontinue taking periodic self-prescribed fiber supplements or anti-diarrheal medications.
- a score ≤24 on the Mini Mental State Examination
- having/reporting fewer than two episodes of FI or being incapable of performing study procedures during the run-in baseline period
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Factorial Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
basic recipe for juice and muffin recipe abbreviated PLB |
|
Experimental: Carboxymethylcellulose
The supplements were prepared as two fruit juice mixtures (each 270 ml) providing 7 g total fiber/d) and two small muffins providing 9 g total fiber/d for 16 g of toal fiber daily. abbreviated CMC |
dietary fiber
|
Experimental: Gum Arabic
The supplements were prepared as two fruit juice mixtures (each 270 ml) providing 7 g total fiber/d) and two small muffins providing 9 g total fiber/d for 16 g of toal fiber daily. abbreviated GA |
Gum acacia dietary fiber
Other Names:
|
Experimental: Psyllium
The supplements were prepared as two fruit juice mixtures (each 270 ml) providing 7 g total fiber/d) and two small muffins providing 9 g total fiber/d for 16 g of toal fiber daily. abbreviated as PSY |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
---|---|
self-report of an incontinent episode on a daily stool diary
|
the date and time of an incontinence episode was reported and the ratio of the number of incontinence episodes to total stools daily was calculated
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
---|---|
self-report of gastro-intestinal symptoms on a daily symptom record
|
The amount of GI symptoms reported were flatus, belching, bloating, abdominal cramping, nausea, a feeling of fullness, and stomach upset using a categorical scale. Number of times of flatus was also reported. The amount of two obfuscating symptoms were also reported. headache and sleepiness. How upsetting/bothersome the symptoms were were also reported. |
self-report of quality of life
|
The Fecal Incontinence Quality of Life tool (FIQL) was used; Rockwood, T.H. et al.
Diseases of the Colon & Rectum.
2000;43(1):9-16.
|
Water-holding capacity of non-frozen of stools
|
Measure was done on stools of 52 randomly selected subjects (13 from each group) Established method of Wenzl, H. et al.
Gastroenterology.
1995;108(6):1729-38 used.
|
Gel formation of non-frozen stools
|
Measure was done on stools of 52 randomly selected subjects (13 from each group); Established method of Fischer, M.H. et al.Carbohydrate Research 2004;339(11): 2009-2017.
|
Total dietary fiber content of feces
|
Measured in composites of all stools from baseline and supplement periods and non-frozen stools Established method of Theander O, et al. J AOAC Int. 1995;78(4):1030-44 used. |
Self-report of amount of supplement consumed
|
reported by fractions on supplement intake form and return of unconsumed portion was assessed by study team
|
amount of fecal incontinence
|
subjects self-reported greatest amount of soiling (from soling of tissue between buttocks to shoes or floor)
|
wet and dry weights of collected stools and percentage of water content
|
collected stools were weighed and freeze-dried to constant weight; percentage of water content was calculated from these values
|
Other Outcome Measures
Outcome Measure |
Measure Description |
---|---|
self-reported rating of consistency of continent stools on a daily stool diary
|
the Stool Consistency Classification System used was shown to be valid and reliable
|
usual diet intake
|
written record of all food and drink consumed
|
report of additional fluid intake
|
subjects checked whether the drank required amount of additional fluid and wrote the date and time of drinking
|
absorbent pad soiling
|
subjects indicated number of absorbent products that were soiled on stool diary and and saved and returned them to be assessed by study team
|
self-report of any stools not collected
|
reported on stool diary daily with reason for not collecting
|
Stool Color change
|
date and time a stool color change was observed after swallowing a capsule with a decoy or marker dose of a food dye; date and time capsule was taken was also reported
|
in vitro fiber degradation
|
nested experiment of in vitro degradation of each dietary fiber by stools of subjects using established procedure reported in Bliss, D.Z. et al.
Nurs.
Res.
2001, 50, 203-213.
|
total dietary fiber content of fiber sources used in Study
|
established method of Theander O. et al.
J AOAC Int.
1995;78(4):1030-44 used.
|
Personal Goals of Treatment for Fecal Incontinence and Satisfaction with Achievement of Goals
|
data obtained by semi-structured interview
|
modifications of preparation of foods, diet intake, and eating pattern to manage fecal incontinence
|
data obtained by semi-structured interview
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Donna Z Bliss, phD, University of Minnesota
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 010M69241
- R01NR007756-01A2 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Fecal Incontinence
-
Batterjee Medical CollegeBenha UniversityCompleted
-
RDD Pharma LtdWithdrawnIdiopathic Fecal IncontinenceIsrael
-
Badr UniversityCompletedFecal Incontinence in ChildrenEgypt
-
Hospital Mutua de TerrassaCompletedGas Incontinence | Soilings, Fecal
-
Nantes University HospitalCompletedConstipation Aggravated | Fecal Incontinence With Fecal UrgencyFrance
-
Queen Mary University of LondonCompletedBowel Incontinence | Faecal Incontinence
-
University of AarhusUniversity of Tromso; Hvidovre University HospitalCompletedFecal Incontinence | Faecal IncontinenceDenmark
-
NICHD Pelvic Floor Disorders NetworkEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedFecal Incontinence | Bowel IncontinenceUnited States
-
Andalusian Initiative for Advanced Therapies -...Iniciativa Andaluza en Terapias AvanzadasCompleted
-
Massarat ZutshiCook Group IncorporatedTerminatedFecal Incontinence | Anal IncontinenceUnited States
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States